MARKET

TNXP

TNXP

Tonix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6500
-0.0263
-3.89%
Pre Market: 0.6500 0 0.00% 05:01 06/01 EDT
OPEN
0.6610
PREV CLOSE
0.6763
HIGH
0.7194
LOW
0.6370
VOLUME
7.57M
TURNOVER
--
52 WEEK HIGH
18.40
52 WEEK LOW
0.3902
MARKET CAP
32.08M
P/E (TTM)
-0.0095
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TNXP stock price target is 2.500 with a high estimate of 2.500 and a low estimate of 2.500.

EPS

TNXP News

More
Tonix Pharmaceuticals Posted Results from Pharmacokinetic Analyses of TNX-102 SL and TNX-601 CR in Advance of Virtual Poster Presentations at the American Society of Clinical Psychopharmacology
NEW YORK, May 21, 2020 -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, posted two posters for the.
GlobeNewswire · 05/21 11:00
Tonix Pharmaceuticals Announces Appointment of Herbert Harris, M.D., Ph.D., as Executive Vice President, Translational Medicine
GlobeNewswire · 05/19 12:00
Can Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Afford To Invest In Growth?
Simply Wall St. · 05/14 16:17
Tonix Pharmaceuticals Q1 EPS $(0.370) Up From $(1.290) YoY
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(0.370) per share. This is a 71.32 percent increase over losses of $(1.290) per share from the same period last year.
Benzinga · 05/12 11:31
Tonix Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights
Four Potential Vaccines in Development to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on the Company’s Horsepox Virus Vaccine Platform Potential Vaccine,.
GlobeNewswire · 05/12 11:30
Tonix Trial Update, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 04/28 15:54
Tonix Pharma completes 50% enrollment in late-stage fibromyalgia study; shares up 12% premarket
Seeking Alpha - Article · 04/24 12:07
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia
GlobeNewswire · 04/24 12:00

Industry

Biotechnology & Medical Research
+1.44%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Symbol
Price
%Change

About TNXP

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates, including one product candidate in clinical development for registration in two indications. TNX-102 SL (cyclobenzaprine hydrochloric acid (HCl) sublingual tablets), is a disintegrating tablet containing cyclobenzaprine (CBP) for sublingual administration. The Company has completed Phase IIb BESTFIT trial of TNX-102 SL for fibromyalgia. It is being evaluated in the Phase III AFFIRM study for the treatment of fibromyalgia. The Company is also conducting AtEase trial, which is a Phase II clinical trial of TNX-102 SL in military-related PTSD. It also has a pipeline of other product candidates, including TNX-301, a fixed dose combination drug product (CDP).
More

Webull offers kinds of Tonix Pharmaceuticals Holding Corp stock information, including NASDAQ:TNXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNXP stock news, and many more online research tools to help you make informed decisions.